A study concerning identification of novel driver genes and therapeutic targets in aggressive cSCC found frequent inactivating mutations (~39%) in KMT2C, a gene which encodes a component of a histone methylation complex involved in transcriptional regulation. Here, KMT2C is linked to skin squamous cell carcinoma.